Syncom Formulations is trading 5% down at ₹20.13; available search results show no clear company-specific announcement explaining the October 26, 2026 decline.
- The latest identified company filing was routine compliance; recent coverage discussed technical trading rather than a new catalyst.
- The broader Indian market opened lower, while pharma and healthcare were session gainers, so the evidence does not establish a market or sector cause.
- No October 26 trading-volume figure was confirmed.